All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Immune fitness and teclistamab response: MajesTEC-1 subanalysis

Jun 11, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM

Bookmark this article

A subanalysis on the impact of immune fitness on response to teclistamab from MajesTEC-1 has been published in Blood by Cortes-Selva et al.1 Researchers compared tumor characteristics and immune profiles of the 165 patients with relapsed/refractory multiple myeloma (RRMM) with response to 1.5 mg/kg teclistamab.

Key learnings:

There was a relationship identified between immune profiles and response to teclistamab.

Most notably, a higher baseline T-cell count in the peripheral blood was associated with improved response.

Patients who did not respond to teclistamab generally possessed immune profiles suggestive of immune suppression and T-cell dysfunction, with higher frequencies of T cells expressing exhaustion markers.

Increased progression-free survival rates were linked to lower frequencies of T cells with exhaustion markers at baseline.

These findings suggest that assessing baseline immune profiles could help predict response to teclistamab and aid in the development of personalized treatment plans.

  1. Cortes-Selva D, Perova T, Skerget S, et al. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1. Blood. 2024. DOI: 1182/blood.2023022823. Online ahead of print.

Related articles


Subscribe to get the best content related to multiple myeloma delivered to your inbox